论文部分内容阅读
目的探讨微剂量肝素皮下注射治疗危重新生儿弥漫性血管内凝血前期(Pre-DIC)的疗效。方法将42例处于弥漫性血管内凝血前期的危重新生儿随机分为治疗组20例,对照组22例。二组均给予共同的综合性治疗措施,治疗组加用微剂量肝素皮下注射治疗,剂量:5U/(kg.次),2h/次;对照组应用常规剂量肝素治疗,即100U/(kg.次),12h/次,皮下注射。观察二组患儿治愈率、病死率、住院天数、住院费用及应用肝素的不良反应。结果治疗组治愈率高于对照组,病死率低于对照组,差异均有统计学意义(P<0.05),治疗组的住院天数及住院费用明显低于对照组,差异均有统计学意义(P<0.05)。治疗组不良反应发生率显著低于对照组,差异均有统计学意义(P<0.05)。结论微剂量肝素定时皮下注射治疗危重新生儿弥漫性血管内凝血前期效果好,可改善危重新生儿预后,不良反应发生率低,使用安全。
Objective To investigate the effect of subcutaneous injection of micro-dose heparin on diffuse pre-DIC in critically ill neonates. Methods Forty-two critically ill newborn infants with diffuse intravascular coagulation were randomly divided into treatment group (n = 20) and control group (n = 22). The two groups were given a common comprehensive treatment, the treatment group plus subcutaneous injection of micro-dose of heparin treatment, dose: 5U / (kg. Times), 2h / times; control group with conventional dose of heparin treatment, that is, 100U / (kg. Times), 12h / time, subcutaneous injection. The cure rate, case fatality rate, days of hospitalization, hospitalization costs and the adverse reactions of heparin were observed in the two groups. Results The cure rate of the treatment group was higher than that of the control group, the case fatality rate was lower than that of the control group, the difference was statistically significant (P <0.05), the hospitalization days and hospitalization costs of the treatment group were significantly lower than those of the control group P <0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion Time-dose subcutaneous injection of heparin subcutaneously in treatment of diffuse intravascular coagulation in critically ill newborns is effective in improving the prognosis of critically ill newborn infants with low incidence of adverse reactions and safe use.